Genitourinary Cancers

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.

A diet high in omega-3 fatty acids and low in omega-6 fatty acids, taken with fish oil, reduced the Ki-67 index in men with prostate cancer on active surveillance.

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.

Regenerative Medicine Advanced Therapy designation was granted to an investigational CAR-T cell therapy for some patients with renal cell carcinoma.

TULSA is a targeted prostate cancer treatment that uses ultrasound to destroy tumors while preserving healthy tissue.

Removing more lymph nodes during surgery may also increase the risk for death after surgery in muscle-invasive bladder cancer.

Cancer is complicated, especially with multiple diagnoses, oncologists, tests and integrative treatments, but AI can be a helpful tool.

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic kidney cancer.

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function.

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

An expert provides answers to pressing questions regarding different aspects of a kidney cancer journey, including stage, grade and treatment options.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo.

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed after checkpoint inhibitors.

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows.

Among patients with previously treated advanced clear cell renal cell carcinoma (RCC) Welireg continued to show some benefits, though not to overall survival.

From Princess Kate entering ‘a new phase of recovery’ to a Rock and Roll Hall of Famer’s blood cancer announcement, here’s what’s happening in the cancer space this week.

I stopped pondering why cancer happened to me and instead focused on achieving my goals and taking life on.

Fatigue is a common side effect that may linger for years following cancer treatment. Experts and survivors talk about ways to help find a balance between life and fatigue.

From Danielle Fishel and Rick Steves announcing their diagnosis to the “Emily in Paris” star discussing her cancer experience, here’s what’s happening in the oncology space this week.

One expert explained why ‘it’s very important to know what’s going on’ with regard to new renal cell carcinoma treatments.

Androgen receptor pathway inhibitors were shown to better treat patients with metastatic castration-resistant prostate cancer and improved survival.

Afinitor did not improve relapse-free survival in patients with non-clear cell renal cell carcinoma — a kidney cancer subtype linked to poor prognosis.

Patients with locally advanced muscle-invasive bladder cancer may benefit from dose-dense gemcitabine and cisplatin.

Understanding how I fit in matters to me but figuring out my identity in the cancer space is not always easy.

Considering nutrition and frailty earlier on may help patients achieve better health-related quality of life during kidney cancer and bladder cancer.